Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Sequana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sequana Medical Completes Enrollment in Phase 2a SAHARA I DSR Study, Reports Disease-Modifying Profile for Short Term DSR and Provides Business Update","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Sequana Medical"}]

Sequana Medical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sequana Medical Completes Enrollment in Phase 2a SAHARA I DSR Study, Reports Disease-Modifying Profile for Short Term DSR and Provides Business Update

Details:

Interim results from ten evaluable patients after completion of intensive DSR 1.0 (alfapump DSR Therapy) period demonstrated that DSR therapy safely, effectively and rapidly eliminated persistent congestion and restored euvolemia, resulting in mean weight loss of 6kg.

Lead Product(s): Alfapump DSR Therapy,Dapagliflozin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: DSR 1.0

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 19, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY